It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year.

Cybin’s Programs For MDD And Anxiety Disorders

Cybin Inc. (NYSE: CYBN) outlined its near-term goals regarding the CYB003 and CYB004 clinical programs, which CEO Doug Drysdale believes “will provide important information” to help strengthen the company in the progression of its investigational therapies towards undertreated mental health conditions.

The proprietary psilocybin analog CYB003 is being assessed in a Phase 1/2a study for the treatment of Major Depressive Disorder (MDD). 

As a deuterated form of the first-gen psychedelic, CYB003 is designed to potentially address the challenges and limitations of oral psilocybin, such as variability in plasma levels, drug onset, and duration of effect. 

Interim results from this Phase 1/2a trial will be shared in February and will include the safety and pharmacokinetic (PK) profile of the drug, such as observations of the characteristics and duration of its psychedelic effect.

The findings would provide information on the necessary dose ranging for the ongoing trial plus upcoming clinical studies of CYB003, as the company aims to secure more consistent and predictable dosing, and reduced intra- and interindividual variability.

The other proprietary psychedelic, CYB004, is an intravenous …

Full story available on